Replies to post #229411 on Anavex Life Sciences Corp (AVXL)

[ExtremelyBullishZig]

Since the full enrollment PR is not legally required...we will get it but at the most opportune time instead of right when it happens.

[Investor2014]

. The options shall vest upon the achievement of a certain clinical trial milestone with respect to the Issuer's Phase 2 clinical trial program of Anavex(R)2-73 for the treatment of Rett syndrome.

We don't know what the "certain clinical trial milestone" for the Rett program is. Could also involve the Peadiatric trial and most likely does.

Any PR sooooon on the PDD and the adult Rett trials will probably not be related to these new option awards.

I guess the options awarded to Missling and Boenisch in January 2018 will likely have vested.

The options shall vest upon the achievement of 50% enrollment in the Company's Alzheimer's disease and Parkinson's disease dementia clinical trials.

In April 2019 Boenisch Sandra also got options vesting when

The options shall vest upon the achievement by the Company of 100% patient enrollment in the Company's Phase 2b/3 Alzheimer's disease and Phase 2 Parkinson's disease dementia clinical trials.

So that will be a while yet.

[tredenwater2]

“So are we going to get a fully enrolled PDD and RETT trial PR?

I believe is what makes the most sense after the granting of these options.”

Dont forget the Alzheimer’s %50 enrollment!!!!!! Trials are rolling and cant be stopped...well, unless their is very obvious results! I say peek at the halfway point Mr FDA! What are you scared of? Efficacy?

2020!!!!!

Tred